Amrutanjan Health Care Q3 PAT at Rs 19.45 cr; declares second interim dividend of Re 1
AMRUTANJAN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 8.7 pts more than Nifty Microcap 250 and 9.8 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Amrutanjan Health Care reported Q3 FY26 revenue of Rs 141.04 cr, up about 15 percent from Rs 122.75 cr in Q3 FY25. Net profit was Rs 19.45 cr versus Rs 19.24 cr earlier. For 9 months FY26, revenue rose to Rs 352.78 cr from Rs 316.40 cr, with PAT up to Rs 41.73 cr from Rs 35.66 cr. Board declared a second interim dividend of Re 1 per share for FY26. Results include an exceptional charge of Rs 1.25 cr for new labour codes. Auditor issued an unmodified limited review report.
Steady Q3 with double-digit revenue growth and a second interim dividend is positive for shareholders. Watch margin trends and follow-on labour code impact.